Michael Lin, MD
Endocrinology, Diabetes & Metabolism · San Gabriel, CANPI 1285661819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Insulet Corporation at 50.8% of the total. Reporting peaked in 2021 at $231 and has fallen 82.7% since, to $40 in 2023. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 18 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$177
- Integra Lifesciences Corporation$88
- Sanofi$40
- Dexcom, Inc.$17
- Novartis$14
- EPI Health, LLC$12
What the payments were for
- Food & beverage$348100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 13 | $177 |
| Integra Lifesciences Corporation | 1 | $88 |
| Sanofi | 1 | $40 |
| Dexcom, Inc. | 1 | $17 |
| Novartis | 1 | $14 |
| EPI Health, LLC | 1 | $12 |
How this compares
$348 in reported general payments places this provider in the 30th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 1,011 | $809,848 |
| RybelsusSemaglutide | 402 | $535,497 |
| OzempicSemaglutide | 298 | $430,388 |
| FarxigaDapagliflozin Propanediol | 413 | $339,462 |
| JanuviaSitagliptin Phosphate | 397 | $309,404 |
| TradjentaLinagliptin | 209 | $154,527 |
| TrulicityDulaglutide | 126 | $134,862 |
| Tresiba Flextouch U-200Insulin Degludec | 98 | $130,008 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 354 | $128,704 |
| JanumetSitagliptin Phos/Metformin Hcl | 164 | $123,568 |
| Humalog Mix 50-50 KwikpenInsulin Lispro Protamin/Lispro | 320 | $108,489 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 118 | $100,963 |
| Teriparatide | 36 | $86,278 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 92 | $85,814 |
| MounjaroTirzepatide | 55 | $76,822 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in San Gabriel
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.